<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-9933</journal-id>
<journal-title><![CDATA[Revista Información Científica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. inf. cient.]]></abbrev-journal-title>
<issn>1028-9933</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas Guantánamo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-99332019000400458</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores relacionados con el efecto de fármacos antagonistas de la vitamina K]]></article-title>
<article-title xml:lang="en"><![CDATA[Factors related to the effect of vitamin K antagonist drugs]]></article-title>
<article-title xml:lang="pt"><![CDATA[Fatores relacionados ao efeito de drogas antagonistas da vitamina K]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Isalgué Rodríguez]]></surname>
<given-names><![CDATA[Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Céspedes Isalgué]]></surname>
<given-names><![CDATA[Eidalis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente &#8220;Dr. Agostinho Neto&#8221;  ]]></institution>
<addr-line><![CDATA[ Guantánamo]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Facultad de Ciencias Médicas  ]]></institution>
<addr-line><![CDATA[ Guantánamo]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>98</volume>
<numero>4</numero>
<fpage>458</fpage>
<lpage>468</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-99332019000400458&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-99332019000400458&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-99332019000400458&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  la prescripción de fármacos inhibidores de la vitamina K exige el control del efecto anticoagulante.  Objetivo:  caracterizar a los pacientes con antecedentes de tratamiento con warfarina sódica al momento del ingreso en la unidad de terapia intensiva del Hospital General Docente &#8220;Dr. Agostinho Neto&#8221; durante el periodo 2016-2018.  Método:  se realizó estudio analítico, retrospectivo y longitudinal. Se estudiaron 54 pacientes con las características señaladas, que se agruparon en un grupo control (n=16) con anticoagulación adecuada y un grupo estudio (n=38) también con anticoagulación adecuada. Se estudiaron variables sociodemográficas, clínicas y de laboratorio.  Resultados:  Un total de 16 pacientes presentó nivel adecuado de anticoagulación y en, 38, nivel de anticoagulación fue inadecuado. La warfarina sódica se indicó más en pacientes con prótesis valvular cardiaca mecánica (20,0 %), y en estos fue más común la anticoagulación inadecuada. Los factores más relacionados con la anticoagulación adecuada fueron la supervisión médica frecuente (p=0,0000), que no usaron fármacos que interfieran con la acción del fármaco (p=0,0000) y el cumplimiento del tratamiento (p=0,0000). En 22 pacientes se presentaron complicaciones hemorrágicas y la más común fue la hemorragia cerebral y, 16, presentaron complicaciones tromboembólicas y la más frecuente fue el embolismo cerebral. Fallecieron 3 pacientes por complicaciones hemorrágicas y 9 por complicaciones tromboembólicas. En 21 pacientes la indicación del fármaco fue inapropiada.  Conclusiones:  se revela la necesidad del control de la adecuada adherencia terapéutica del paciente pues el inadecuado efecto anticoagulante genera complicaciones que pueden determinar la muerte del paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  the prescription of vitamin K inhibitor drugs requires control of the anticoagulant effect.  Objective:  to characterize patients with a history of treatment with warfarin sodium at the time of admission to the intensive care unit of the General Teaching Hospital &#8220;Dr. Agostinho Neto&#8221; during the 2016-2018 period.  Method:  an analytical, retrospective and longitudinal study was carried out. 54 patients with the characteristics indicated were studied, which were grouped in a control group (n=16) with adequate anticoagulation and a study group (n=38) also with adequate anticoagulation. Sociodemographic, clinical and laboratory variables were studied.  Results:  A total of 16 patients presented adequate level of anticoagulation and, in 38, level of anticoagulation was inadequate. Sodium warfarin was indicated more in patients with mechanical cardiac valve prostheses (20.0%), and inadequate anticoagulation was more common in these. The factors most related to adequate anticoagulation were frequent medical supervision (p=0.0000), who did not use drugs that interfere with the action of the drug (p=0.0000) and treatment compliance (p=0.0000). In 22 patients there were hemorrhagic complications and the most common was cerebral hemorrhage and, 16, they presented thromboembolic complications and the most frequent was cerebral embolism. Three patients died from bleeding complications and 9 from thromboembolic complications. In 21 patients the indication of the drug was inappropriate.  Conclusions:  the need to control the adequate therapeutic adherence of the patient is revealed because the inadequate anticoagulant effect generates complications that can determine the death of the patient.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  a prescrição de medicamentos inibidores da vitamina K requer controle do efeito anticoagulante.  Objetivo:  caracterizar pacientes com histórico de tratamento com varfarina sódica no momento da admissão na unidade de terapia intensiva do Hospital Geral de Ensino &#8220;Dr. Agostinho Neto&#8221; no período 2016-2018.  Método:  estudo analítico, retrospectivo e longitudinal. Foram estudados 54 pacientes com as características indicadas, os quais foram agrupados em um grupo controle (n=16) com anticoagulação adequada e um grupo estudo (n=38) também com anticoagulação adequada. Foram estudadas variáveis sociodemográficas, clínicas e laboratoriais.  Resultados:  Um total de 16 pacientes apresentou nível adequado de anticoagulação e, em 38, o nível de anticoagulação foi inadequado. A varfarina sódica foi mais indicada em pacientes com próteses valvares cardíacas mecânicas (20,0%), sendo a anticoagulação inadequada mais comum. Os fatores mais relacionados à anticoagulação adequada foram a supervisão médica frequente (p=0,0000), que não utilizou medicamentos que interferem na ação do medicamento (p=0,0000) e adesão ao tratamento (p=0,0000) Em 22 pacientes houve complicações hemorrágicas e a mais comum foi hemorragia cerebral; 16 apresentaram complicações tromboembólicas e a mais frequente foi embolia cerebral. Três pacientes morreram por complicações hemorrágicas e 9 por complicações tromboembólicas. Em 21 pacientes, a indicação do medicamento foi inadequada.  Conclusões:  a necessidade de controlar a aderência terapêutica adequada do paciente é revelada, pois o efeito anticoagulante inadequado gera complicações que podem determinar a morte do paciente.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[coagulación]]></kwd>
<kwd lng="es"><![CDATA[anticoagulación]]></kwd>
<kwd lng="es"><![CDATA[fármacos antagonistas de la vitamina K]]></kwd>
<kwd lng="en"><![CDATA[coagulation]]></kwd>
<kwd lng="en"><![CDATA[anticoagulation]]></kwd>
<kwd lng="en"><![CDATA[vitamin K antagonist drugs]]></kwd>
<kwd lng="pt"><![CDATA[coagulação]]></kwd>
<kwd lng="pt"><![CDATA[anticoagulação]]></kwd>
<kwd lng="pt"><![CDATA[drogas antagonistas da vitamina K]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaramillo]]></surname>
<given-names><![CDATA[SRG]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[GJD]]></given-names>
</name>
<name>
<surname><![CDATA[Pinilla]]></surname>
<given-names><![CDATA[RAE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de los anticoagulantes orales directos en la práctica clínica]]></article-title>
<source><![CDATA[Rev Fac Med]]></source>
<year>2016</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>295-308</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morimoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wada]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ueda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies]]></article-title>
<source><![CDATA[J Cardiol]]></source>
<year>2015</year>
<volume>66</volume>
<page-range>466-74</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belmar]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[ALM de]]></given-names>
</name>
<name>
<surname><![CDATA[Bada]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Galván]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevos anticoagulantes orales en pacientes con enfermedad renal crónica]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2016</year>
<volume>365</volume>
<page-range>981-2</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mena Bouza]]></surname>
<given-names><![CDATA[YZ]]></given-names>
</name>
<name>
<surname><![CDATA[Elias Sierra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Esteban Soto]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Elías Armas]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Betancourt]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Índice predictivo de la anticoagulación con antagonistas de la vitamina K]]></article-title>
<source><![CDATA[RIC]]></source>
<year>2018</year>
<volume>97</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>307-14</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruff]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Deenadayalu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2014</year>
<volume>383</volume>
<page-range>955-62</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andreu Cayuelas]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Pastor-Pérez]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Puche]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Mateo-Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Alberola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente]]></article-title>
<source><![CDATA[Rev Esp Card]]></source>
<year>2016</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-40</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goire Guevara]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cuza Díaz]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Fourier Calzado]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[González Marrero]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Montero Vega]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo de complicaciones tromboembólicas cerebrales en pacientes con fibrilación auricular permanente no valvular]]></article-title>
<source><![CDATA[RIC]]></source>
<year>2019</year>
<volume>98</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-87</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis]]></article-title>
<source><![CDATA[J Cardiovasc Med (Hagerstown)]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>873-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review]]></article-title>
<source><![CDATA[Front Aging Neurosci]]></source>
<year>2018</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferro]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bousser]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Canhão]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coutinho]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Crassard]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dentali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis-endorsed by the European Academy of Neurology]]></article-title>
<source><![CDATA[Eur J Neurol]]></source>
<year>2017</year>
<volume>24</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1203-13</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pisters]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Nieuwlaat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[CB de]]></given-names>
</name>
<name>
<surname><![CDATA[Crijns]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anovel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2010</year>
<volume>138</volume>
<page-range>1093-100</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Yousef]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[7004-3-Score same-tt2r2 alto y eventos mayores adversos en pacientes anticoagulados por fibrilación auricularno valvular. Congresos]]></article-title>
<source><![CDATA[Rev Esp Card]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso del tratamiento antitrombótico en pacientes con fibrilación auricular en atención primaria]]></article-title>
<source><![CDATA[Rev Esp Card]]></source>
<year>2014</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>419-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Frade Ruiz]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Cuellar Gamboa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualidades en trombosis]]></article-title>
<source><![CDATA[Med Int Méx]]></source>
<year>2016</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>103-14</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Llisterri]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso del tratamiento antitrombótico según la escala CHA2DS2-VASc en los pacientes confibrilación auricular]]></article-title>
<source><![CDATA[Rev Esp Card]]></source>
<year>2014</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>150-1</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
